C12Y 108/01008
Protein-disulfide reductase , i.e. thioredoxin
Official title: Protein-disulfide reductase (1.8.1.8), i.e. thioredoxin
C12Y108/01008 (Protein-disulfide reductase , i.e. thioredoxin) appears on 30 US grants and 34 published applications in this corpus.
Search patents in C12Y- Granted patents
- 30
- Published applications
- 34
- Assignees
- 31
- Inventors
- 103
- Latest grant
- 30 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 3 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 2 |
| 2003 | 4 | 1 |
| 2004 | 1 | 2 |
| 2005 | 1 | 2 |
| 2006 | 1 | 0 |
| 2007 | 1 | 2 |
| 2008 | 0 | 0 |
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 1 |
| 2013 | 1 | 1 |
| 2014 | 1 | 0 |
| 2015 | 0 | 2 |
| 2016 | 0 | 0 |
| 2017 | 1 | 2 |
| 2018 | 0 | 0 |
| 2019 | 0 | 2 |
| 2020 | 0 | 1 |
| 2021 | 1 | 3 |
| 2022 | 1 | 2 |
| 2023 | 0 | 3 |
| 2024 | 1 | 2 |
| 2025 | 2 | 2 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Thioredoxin mutant, preparation method thereof, and application thereof in production of recombinant fusion protein30 Dec 2025US 12,509,665 B2Chengdu Enzpro Biotechnology Co., Ltd
- Extracellular vesicles derived from recombinant microorganism including polynucleotide encoding target protein and use thereof23 Sep 2025US 12,419,836 B2Medytox Inc.
- Fusion protein between short form rod-derived cone viability factor and a hydrophilic peptide3 Sep 2024US 12,076,367 B2Pharma Cinq, LLC
- Increasing plant growth and yield by expression of an m-type thioredoxin28 Jun 2022US 11,371,053 B2Benson Hill, Inc.
- Fusion protein between short form rod-derived cone viability factor and a hydrophilic peptide16 Mar 2021US 10,946,063 B2Welltat Ophthalmics Corporation
- Treatment of alzheimer's disease with vascular progenitor-derived exosomes enriched with micrornas or thioredoxin26 Feb 2026US 2026/0055403 A1University of Maryland, Baltimore
- Biosynthesis Of Apocarotenoids By Controlling Oxidative Stress5 Jun 2025US 2025/0179504 A1Agency for Science, Technology and Research
- Target molecule reduction method, reduction device, and electrode8 May 2025US 2025/0145661 A1Panasonic Intellectual Property Management Co., Ltd.
- Fusion protein between short form rod-derived cone viability factor and a hydrophilic peptide14 Nov 2024US 2024/0374683 A1Pharma Cinq, LLC
- Vector encoding rod-derived cone viability factor and human igk signal sequence17 Oct 2024US 2024/0342313 A1Pharma Cinq, LLC
Most cited
By later US patents
- Expression of heterologous proteins94US 6,361,969 B1Chiron Corporation · 2002
- Peptide and protein fusions to thioredoxin and thioredoxin-like molecules54US 5,292,646 AGenetics Institute, Inc. · 1994
- Peptide and protein fusions to thioredoxin, thioredoxin-like molecules, and modified thioredoxin-like molecules52US 5,646,016 AGenetics Institute, Inc. · 1997
- Method and ophthalmic composition for the prevention and reversal of cataracts26US 4,771,036 AThe Trustees of Columbia University in the City of New York · 1988
- Neutralization of food allergens by thioredoxin18US 5,792,506 AThe Regents of the University of California · 1998